US pharmaceutical giant Johnson and Johnson on Friday said it has applied for Emergency Use Authorization (EUA) of its single-dose coronavirus vaccine in India. Earlier on Monday, the company had said that it is looking forward to the discussion with the Government of India.
In a statement, a Johnson & Johnson India spokesperson said, "On August 5, 2021 Johnson & Johnson Pvt Ltd applied for EUA of its single-dose COVID-19 vaccine to the government of India. This is an important milestone that paves the way for bringing the company's single-dose COVID-19 vaccine to the people of India. And the rest of the world, through a collaboration with Biological E Limited. Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson COVID-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX Facility."
The approval of the vaccine of J&J's vaccine is based on the efficacy and security data of the 3rd phase trials. According to company, its single-shot vaccine is 85 percent effective in preventing serious illness in all areas. And reduces the hospitalizations related to Covid-19.
On the other hand, India on Friday reported 44,643 new coronavirus infections taking the total tally to 3,18,56,757. Meanwhile, the active cases registered an increase for the third consecutive day. The death toll climbed to 4,26,754 with 464 fresh fatalities.
Also Read:
Like and Follow us on :
